Stroke Research and Treatment / 2018 / Article / Tab 1

Clinical Study

Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study

Table 1

Baseline demographical and clinical characteristics of the study population (n=83) and bivariate comparison between patients treated and not treated. given as median (interquartile range). All other data are reported as absolute number of subjects (%).

ASAControlsp value
n=36n=47

Demographic characteristics
Female sex24 (66.7)33 (70.2)0.730
Age66 (54-72)68 (60-73)0.429
Education ≥9 years11 (32.4)18 (42.9)0.582
Body Mass Index0.551
 25-3018 (50.0)13 (27.6)
 ≥306 (16.7)9 (19.1)
Risk factors
Arterial hypertension17 (47.2)29 (61.7)0.188
Diabetes mellitus1 (2.8)1 (2.1)1.000
Hypercholesterolemia26 (72.2)29 (61.7)0.315
Hypertriglyceridemia8 (22.2)5 (10.6)0.150
Current smoking6 (16.7)7 (14.9)0.826
Previous smoking habit11 (30.6)10 (21.3)0.335
Excessive Alcohol consumption9 (25.0)11 (23.4)0.866
Hyperhomocysteinemia6 (16.7)12 (25.5)0.077
Carotid atheroma3 (8.3)1 (2.1)0.312
Medical history
History of atrial fibrillation1 (2.8)-0.434
Ischemic Heart Disease1 (2.8)-0.434
Heart failure---
Migraine with aura4 (11.1)2 (4.3)0.396
Migraine without aura7 (19.4)12 (25.5)0.513
Treatments
Statins6 (16.7)7 (14.9)0.826
Fibrate1 (2.8)-0.434
ACE inhibitors13 (36.1)3 (6.4)0.001
ARB6 (16.7)15 (31.9)0.113
Beta-blockers6 (16.7)5 (10.6)0.422
Calcium channel blockers3 (8.3)10 (21.3)0.135
Diuretics8 (22.2)11 (23.4)0.899
Anti-arrhythmic-1 (2.1)1.000
Oral hypoglycaemic-2 (4.3)0.503
Insulin---
Nitrated2 (5.6)-0.185
Lesion location
Basal ganglia5 (13.9)11 (23.4)0.276
Cerebellum2 (5.6)2 (4.3)1.000
Brainstem3 (8.3)10 (21.3)0.135
Sub-cortical29 (80.6)39 (83.0)0.776
Peri-ventricular23 (63.9)32 (68.1)0.689
Leukoaraiosis12 (33.3)19 (40.4)0.508
Cortical atrophy12 (33.3)12 (25.5)0.437
Sub-cortical atrophy10 (27.8)6 (12.8)0.086
Right side31 (86.1)43 (91.5)0.492
Left side34 (94.4)4 (89.4)0.693
Cognitive and behavioural tests
ADL score6 (6-6)6 (6-6)0.862
IADL score8 (8-8)8 (8-8)0.134
MMSE score29 (27-30)29 (27-30)0.874
BDI score3,5 (1,75-7)5 (1-7)0.917
HDRS score11 (14-15,5)13 (9-14,5)0.284
MADRS score6 (2,5-10,5)8 (3-12,5)0.299
IQ-code score81 (78,5-85,5)81,5 (79-87)0.476

ACE inhibitors: Angiotensin-Converting-Enzyme inhibitors; ARB: Angiotensin-Receptor Blockers; ADL: Activities of Daily Living; IADL: Instrumental Activities of Daily Living; MMSE: Mini-Mental State Examination; BDI: Beck Depression Inventory; HDRS: Hamilton Depression rating Scale; MADRS: Montgomery-Asberg Depression Rating Scale; IQ-code: Informant Questionnaire on Cognitive Decline in the Elderly.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.